AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04701307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study NCT04714372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20
Description: Daratumumab 1800 mg co-formulated with 30,000 units of hyaluronidase (rHuPH20) given subcutaneously into subcutaneous tissue of the abdomen approximately 3 inches \[7.5 cm\] to the right or left of the navel over approximately 3-5 minutes on Day -12 and Day -5 prior to the 1st FT538 infusion, and on Day +3, Day+10, and Day+17 approximately 48 hours after each FT538 infusion.
Study NCT05577455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical prescription before ovulation
Description: Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
Study NCT05577455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical prescription before ovulation
Description: Medical prescription before ovulation, modified two solstices pill and Si-Wu-Tang: 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 10g of Mo Han Lian (Yerbadetajo herb), 15g of Gou Qi Zi (Fructus lycii), 20g of Tu Si Zi (Semen cuscutae), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), 20g of Sheng Shan Yao (Rhizoma Dioscoreae), 15g of Fu Pen Zi (Raspberry), and 15g of Shan Yu Rou (Fructus corni). The medical prescription is initiated on the fifth day of menstruation and is taken continuously for 10-15 days.
Study NCT05577455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical prescription after ovulation
Description: Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
Study NCT05577455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical prescription after ovulation
Description: Medical prescription after ovulation, modified Er Xian decoction for promoting fertilization and Si-Wu-Tang: 10g of Xian Mao (Curculigo orchioides), 15g of Xian Ling Pi (Epimedium Herb), 15g of Ba Ji Tian (Morinda officinalis), 20g of Tu Si Zi (Semen cuscutae), 15g of Nv Zhen Zi (Fructus Ligustri Lucidi), 15g of Zi Shi Ying (Fluoritum), 15g of Shu Di (Radix Rehmanniae Preparata), 10g of Dang Gui (Angelica sinensis), 10g of Bai Shao (Paeonia lactiflora Pallas), and 10g of Chuan Xiong (Szechwan Lovage Rhizome). The medical prescription is administered continuously for 10-15 days after ovulation, based on follicle development and endometrial growth monitored by ultrasound.
Study NCT04714372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT538
Description: FT538 is administered as an IV infusion via gravity using an IV administration set with an in-line filter at the patient's assigned dose levels (DL) on Day 1, Day 8, and Day 15
Study NCT04714372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2 is administered as a 1 hour intravenous (IV) infusion per institutional guidelines once a day on 2 consecutive days (Day -4, and Day -3).
Study NCT04714372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m\^2 is administered as a 2 hour intravenous (IV) infusion per institutional guidelines once a day on the same days that fludarabine is given.
Study NCT05220657 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Submaximal exercise test
Description: A 25-min submaximal exercise test on ergocycle under fasting condition. Gas exchanges are measured during all the test.
Study NCT06577935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT05082025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given by IV
Study NCT04641637 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TACE
Description: Through a 7 French sheath placed through a single femoral arterial puncture, a guide catheter (Cobra 1 Guide Catheter, Mach 1, Boston Scientific Corporation, Marlborough, USA) is placed at the coeliac axis. From the digital subtraction angiography (DSA), the number of arterial tumor feeders to the HCC is identified. One or more feeder(s) is to be catheterized for delivery of therapeutic agent using a 2.4 French microcatheter (Merit Maestro, Merit Medical Systems, Utah, USA), and the other feeder(s) is occluded with a balloon catheter using 0.1 to 0.2mL diluted contrast for inflation (4mm x 10mm Temporary Occlusion Balloon Catheter, Occlusafe, Terumo Clinial Supply, Gifu, Japan). The occlusion target could be a feeder or a common trunk leading to a number of feeders. The therapeutic agent was delivered under fluoroscopic control until the vasculature of the whole tumors is entirely filled, which was assessed with DSA and non-contrast CT performed at the completion of the procedure.
Study NCT05082025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Given by IM
Study NCT05640544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound and light stimulation in Gamma band
Description: We expect to screen out the efficacy of Gamma band in the prognosis and treatment of disorders of consciousness by various frequencies of stimulation.~Optical stimulation:~A computer program is used to control the flashing frequency of LED lights for stimulation. The serial port can convert the parallel data characters of the computer CPU into a continuous serial data stream. According to the frequency designed by experiment (10Hz, 20hz, 40hz, 80hz), we modulate the flicker frequency of LED lamp. LED lamp uses T8 lamp, diameter 25.4 mm, length 620 mm, and power 20W.~Acoustic stimulation:~We use Adobe Audition CC 2022 to modulate the tones. The tones modulated to 10Hz, 20Hz, 40Hz and 80Hz are play by noise-canceling headphones to the patients.
Study NCT05277363 — intervention group
Intervention type: OTHER
Intervention: None (Observational study)
Description: No investigational intervention, marketed product, or placebo will be administered to study participants in this study.
Study NCT05557682 — intervention group
Intervention type: OTHER
Intervention: composite restorative treatment
Description: Restorative treatment using dental materials
Study NCT05527327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traxi® Panniculus Retractor
Description: This is an adhesive medical device designed to retract a pannus during cesarean section. It will be applied to prospective participants according to manufacturer instructions, just prior to the detailed anatomic ultrasound.
Study NCT05708664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: precision breast conserving surgery guided by wire guided localization combined with MDCT guided 3D reconstruction
Description: Local anesthesia was induced by using 1% lidocaine before wire location. The wire (localization set, PAJUNK) was placed in the superior, inferior, lateral and interior edge of the tumor through a 20-gauge needle using US guidance one day before BCS, respectively. Then, the patient underwent an immediate supine contrast enhanced CT (Philips Brilliance iCT) scan of the breast. The radiologist performed 3D reconstruction of CT images prior to surgery. Finally, the surgical procedures were performed by experienced breast surgeons combing 3D reconstruction of CT images and wire localizations one day after the localization.
Study NCT04894188 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Intensity modulated radiation therapy (IMRT), with 50 Gy in 25 daily fractions (2 Gy/fraction, 5 fractions weekly) for 5 weeks (week 1 - week 5).
Study NCT04894188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin 3.6 MG
Description: Gosereline 3.6mg sc injection at week 1, week 5, and week 9
Study NCT04894188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 MG
Description: Gosereline 3.6mg sc injection at week 1, week 5, and week 9
Study NCT04766450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl cysteine
Description: NAC exhibits potent anti-oxidant activity in the cell through augmentation of intracellular GSH, which is a major component of the pathways by which cells are protected from OTS, and its direct scavenging activity of free radicals by providing sulfhydryl groups. Additionally, NAC treatment exhibits anti-inﬂammatory effects via inhibition of NF-κB activation and reducing subsequent cytokine production . Mitochondria-protective mechanisms of NAC may also be related to its anti-oxidant and anti-inﬂammatory properties
Study NCT04894188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy
Description: Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
Study NCT04894188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical prostatectomy
Description: Eligible patients will undergo robotic-assisted radical prostatectomy and pelvic lymph node dissection
Study NCT05064891 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound guided injection
Description: Subdeltoid bursa injection, suprascapular nerve block, or posterior glenohumeral joint injection. The participants should only receive one type of the injection mentioned above.
Study NCT05465473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distalization
Description: Group I: will include 10 patients undergo distalization according to a standardized protocol. Group II: will include 10 patients undergo distalization assisted with low level laser therapy according to a standardized protocol.
Study NCT05693584 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction
Description: diverting the patient's attention with virtual reality glasses
Study NCT05742321 — intervention group
Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping will measure the triple nucleotide repeat in the TCF4 gene and search for other known mutations in other genes Blood sample will be performed (genetic analyses).
Study NCT05742321 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histology
Description: Histology will be performed on flat mounted Descemet membrane obtained after Descemetorhexis
Study NCT05742321 — intervention group
Intervention type: OTHER
Intervention: Collection of data
Description: Collection of data of examination for diagnosis of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
Study NCT06268665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice
Description: Given PO
Study NCT05834153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotaping
Description: This group underwent a KT application on rectus abdominis muscle (RAM), oblique abdominal muscles (OAM) and cesarean incision twice a week for a period of 4 weeks. First, the scar technique will apply using I band with a tension of 50 % on cesarean incision when the patient will be in supine position. Then, tape will apply on RAM using muscle technique from origin to insertion of the muscle with a tension between 15 and 25 %.~Band will start on symphysis pubis with no tension, and then the patient was asked to stretch the abdominal region by deep abdominal respiration, and it will ended on xiphoid process.~Finally, it will perform on the right and left external oblique muscles. The procedure will start with no tension from the bottom end of the 6-12th ribs and then the hip will placed in flexion and rotation to the opposite direction and the band will taped on pubic bone with a tension between 15 and 25 %
Study NCT05834153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical muscle stimulation
Description: It consists of 24 patients who will receive NMES and core stabilization exercises.~The subjects will explain to relax their abdominal muscles while application Stimulation will apply by four large rectangular electrodes placed over the origin (pubic crest) and insertion (xiphoid process) of the rectus abdominis muscles bilaterally. Straps will used to fix the electrodes in place. A frequency of 80 pulses/min and with a pulse width of 0.1-0.5ms, will the parameter settings apply in this study. The total time for the application of stimulation will 30mins and until a good enough observable muscle contraction will achieve a gradual increase in intensity will perform
Study NCT05531097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31679
Description: Single or multiple oral doses of HSK31679
Study NCT05531097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05678114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Myo-inositol (4g/die)
Study NCT04935515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins
Description: Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D
Study NCT04935515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral low dose steroid
Description: Low dose oral methyl prednisolone was added.
Study NCT04935515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Antibiotics with Low dose steroid.
Description: Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given
Study NCT04935515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anti-coagulant
Description: Rivaroxaban was given for minimum 4 weeks depending on D dimer levels
Study NCT05364255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD9833 Oral Solution, 75 mg
Description: Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted
Study NCT06208332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo-Narrative
Description: Photo-Narratives include 1-3 photos of the pediatric patient and their family to tell a story about palliative care topics that are shared with the child's clinicians.
Study NCT05007444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2Et (Caesalpinia spinosa extract)
Description: Patients who meet inclusion criteria will begin taking 4000mg daily, distributed in 2 doses with meals of 2000mg of P2Et extract during neoadjuvant treatment. In case of presenting toxicity, it will be lowered to the next dose level, that is, 2000 mg under the same dosage schedule and 1000 mg following the same principle. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard neoadjuvant therapy and will restart 3 days after having passed the cycle. That is, in the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days after the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
Study NCT05007444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After determining the optimal biological dose (OBD), the patients will be divided into the placebo arm or the treatment arm. In the anthracyclines and cyclophosphamide (AC) phase, the patient will start taking according to the asignation as stated in the drug intervention.
Study NCT06420583 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MTA pulpotomy
Description: 1. Application of rubber dam for isolation, then a standardized access cavity procedure will be performed using a large sterile round end bur in a high-speed handpiece with copious irrigation, a sharp spoon excavator will remove pulpal tissues to the orifice level, bleeding control in the pulp chamber will be achieved by using 5% sodium hypochlorite.~2. gentle condensation of MTA mix in the pulp chamber will be done by a wet sterile cotton pellet and then the rest of the pulp chamber will be filled with Glass Ionomer restoration.~3. The tooth will be restored with a stainless steel crown.
Study NCT06420583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction
Description: After complete Anesthetic application in the affected area, non-surgical extraction will be done.
Study NCT06322303 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (CBD 0%)
Description: Participants are required to vaporize placebo at 0% CBD concentration
Study NCT06322303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD 15%
Description: Participants are required to vaporize CBD at a concentration of 15%.
Study NCT06322303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD 30%
Description: Participants are required to vaporize CBD at a concentration of 30%.
Study NCT04982653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06215716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efruxifermin
Description: Administered by subcutaneous injection
Study NCT06215716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT05344703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Y Balance Plus Visual Perturbations
Description: Stroboscopic glasses will be added to the protocol for the participants to perform the Y-balance lower quarter to examine the differences in Y-balance scores as well as examining the Y-balance's ability to predict injury and concussion with visual perturbations.
Study NCT05344703 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Y balance
Description: Subjects will perform Y-balance without any interventional strategies.
Study NCT04982653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05791084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application with breathing instructions and a sensor to attach around the chest. To be able to train at home before radiotherapy with DIBH starts.
Description: The DIBH-App consists of 1) a mobile application that patients download to their own smart mobile phone, and 2) associated stretch-sensors that are attached around the chest and connected to the mobile phone via Bluetooth. Visually, the graphics is similar to the software used for DIBH in the RT department. Coaching takes place through instructional videos, text, and audio recordings (Image 2). The following information will be recorded and stored: date and time of practice, outcome of each session (including sensor data and calibration parameters), and user behavior within the application (such as screen visits, FAQ sections viewed, and key button presses).
Study NCT04982653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo hepatectomy using small bites fascial method for abdominal wall closure
Study NCT04982653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo hepatectomy using conventional fascial method for abdominal wall closure
Study NCT06286943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short Chain Fatty Acids (SCFAs).
Description: Colon-delivery capsules of SCFAs.
Study NCT06286943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystaline cellulose placebo capsules.
Study NCT06286943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maastricht Acute Stress Task
Description: The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.
Study NCT06286943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maastricht Acute Stress Task
Description: The Maastricht Acute Stress Task. This 15-minute stress-inducing task consists of a 5-minute preparation phase where instructions about the upcoming tasks are given, followed by a 10-minute acute stress phase where the hand immersion trial (HIT) in ice-cold water and mental arithmetic (MA) task is given interchangeably.
Study NCT06286943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No-stress control task
Description: The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
Study NCT06286943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-stress control task
Description: The placebo version of the MAST follows the same structure of the MAST with none of the stress elements. It uses lukewarm water and simple arithmetic's.
Study NCT05004233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection before antiplatelet treatment
Description: Blood sample (17ml) will be collected in the neurovascular department to be processed for platelet ultrastructural analysis before the onset of an antiplatelet treatment